AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18717680 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolaevulinic acid-photodynamic therapy (ALA-PDT)
Number of subjects: 149
Study 18717680 — intervention group
Group type: COMPARATOR
Intervention: Surgical excision (SE)
Number of subjects: 149
Study 16282192 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis-based medicine (Sativex)
Number of subjects: 58
Study 16282192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 12657409 — intervention group
Group type: EXPERIMENTAL
Intervention: Drägersorb Free
Number of subjects: 24
Study 12657409 — intervention group
Group type: EXPERIMENTAL
Intervention: Amsorb
Number of subjects: 24
Study 12657409 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodasorb II
Number of subjects: 24
Study 10910489 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 50
Study 10910489 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 50
Study 10910489 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 50
Study 10910489 — intervention group
Group type: COMPARATOR
Intervention: Control (Thiopental)
Number of subjects: 50
Study 8840078 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone engagement intervention (n=54)
Number of subjects: 450
Study 8840078 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive telephone intervention (n=108)
Number of subjects: 450
Study 8840078 — intervention group
Group type: COMPARATOR
Intervention: Business as usual telephone screening (n=108)
Number of subjects: 450
Study 1389816 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% plain bupivacaine administered at a speed of 10 seconds
Number of subjects: 40
Study 1389816 — intervention group
Group type: COMPARATOR
Intervention: 0.5% plain bupivacaine administered at a speed of 180 seconds
Number of subjects: 40
Study 4070430 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet
Number of subjects: 12
Study 4070430 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Number of subjects: 12
Study 30486659 — intervention group
Group type: EXPERIMENTAL
Intervention: Written informational aid (pamphlet)
Number of subjects: 40
Study 30486659 — intervention group
Group type: COMPARATOR
Intervention: Standard informed consent discussion (no pamphlet)
Number of subjects: 40
Study 29162459 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG-neurofeedback training (up-regulation of beta band activity)
Number of subjects: 0
Study 29162459 — intervention group
Group type: COMPARATOR
Intervention: EEG-neurofeedback training (down-regulation of beta band activity)
Number of subjects: 0
Study 29162459 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG changes (both up and down regulation)
Number of subjects: 0
Study 26626719 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily tobramycin inhalation solution (TIS) 300 mg/5 mL
Number of subjects: 29
Study 26626719 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily tobramycin inhalation solution (TIS) 300 mg/5 mL
Number of subjects: 29
Study 26626719 — intervention group
Group type: COMPARATOR
Intervention: Once-daily versus twice-daily tobramycin inhalation solution (TIS)
Number of subjects: 29
Study 26626719 — intervention group
Group type: COMPARATOR
Intervention: Both once-daily and twice-daily tobramycin inhalation solution (TIS)
Number of subjects: 29
Study 24960387 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Plax Magic
Number of subjects: 38
Study 24960387 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine Cool Blue Agent
Number of subjects: 38
Study 24960387 — intervention group
Group type: EXPERIMENTAL
Intervention: Water and dye
Number of subjects: 38
Study 24960387 — intervention group
Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 38
Study 24960387 — intervention group
Group type: COMPARATOR
Intervention: Control (no mouthwash)
Number of subjects: 38
Study 22342106 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 33
Study 22342106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 22254024 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant (AO) cocktail (Lactaway(©))
Number of subjects: 13
Study 22254024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 16814411 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist care (cardiology registrar and heart failure nurses)
Number of subjects: 113
Study 16814411 — intervention group
Group type: COMPARATOR
Intervention: Control (referred back to general practitioner)
Number of subjects: 113
Study 16814411 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (specialist care and control)
Number of subjects: 113
Study 16444386 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-vacuum device
Number of subjects: 351
Study 16444386 — intervention group
Group type: COMPARATOR
Intervention: Syringe pistol holder
Number of subjects: 351
Study 11907291 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient geriatric unit care
Number of subjects: 1388
Study 11907291 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient geriatric clinic care
Number of subjects: 1388
Study 11907291 — intervention group
Group type: COMPARATOR
Intervention: Usual inpatient care
Number of subjects: 1388
Study 11907291 — intervention group
Group type: COMPARATOR
Intervention: Usual outpatient care
Number of subjects: 1388
Study 9463741 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood glucose monitors (17 devices: 2 visually read, 8 colorimetric, 7 amperometric)
Number of subjects: 50
Study 9463741 — intervention group
Group type: COMPARATOR
Intervention: Dedicated glucose analyser
Number of subjects: 50
Study 8556900 — intervention group
Group type: EXPERIMENTAL
Intervention: Skill-based training program to enhance maternal sensitivity between 6 and 9 months of age
Number of subjects: 82
Study 8556900 — intervention group
Group type: EXPERIMENTAL
Intervention: Skill-based training program to enhance maternal sensitivity
Number of subjects: 82
Study 1977330 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (1 microgram/kg) and Vecuronium (0.2 mg/kg)
Number of subjects: 0
Study 1977330 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (1 microgram/kg) and Atracurium (1.0 mg/kg)
Number of subjects: 0
Study 1977330 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (5 micrograms/kg) and Vecuronium (0.2 mg/kg)
Number of subjects: 0
Study 1977330 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (5 micrograms/kg) and Atracurium (1.0 mg/kg)
Number of subjects: 0
Study 500517 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin stearate in non-fasting subjects
Number of subjects: 0
Study 500517 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin stearate
Number of subjects: 0
Study 500517 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin base
Number of subjects: 0
Study 500517 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated erythromycin base
Number of subjects: 0
Study 31862277 — intervention group
Group type: EXPERIMENTAL
Intervention: Jacobson's relaxation technique (20‐30min daily for three consecutive days)
Number of subjects: 80
Study 31862277 — intervention group
Group type: COMPARATOR
Intervention: Routine care and treatment (control group)
Number of subjects: 80
Study 30087153 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL/kg fluid bolus every 15 min for up to 4 hours
Number of subjects: 75
Study 30087153 — intervention group
Group type: COMPARATOR
Intervention: 20 mL/kg fluid bolus every 15 min for up to 4 hours
Number of subjects: 75
Study 30087153 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 75
Study 27522514 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive blood pressure monitoring
Number of subjects: 58
Study 27522514 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive blood pressure monitoring
Number of subjects: 58
Study 25741969 — intervention group
Group type: COMPARATOR
Intervention: Short-course ARV (antenatal zidovudine with single-dose nevirapine)
Number of subjects: 753
Study 25741969 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple ARV prophylaxis until breastfeeding cessation
Number of subjects: 753
Study 23506731 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine ER (4 mg) daily
Number of subjects: 197
Study 21254985 — intervention group
Group type: EXPERIMENTAL
Intervention: Underbody forced-air warming
Number of subjects: 129
Study 21254985 — intervention group
Group type: EXPERIMENTAL
Intervention: Underbody resistive heating mattress
Number of subjects: 129
Study 21254985 — intervention group
Group type: COMPARATOR
Intervention: Passive insulation
Number of subjects: 129
Study 20021912 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 U/(kg.d) growth hormone (Somatropin, S19990021) in A(1) and B(1) groups
Number of subjects: 210
Study 20021912 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 U/(kg.d) growth hormone in A(2) and B(2) groups
Number of subjects: 210
Study 20021912 — intervention group
Group type: COMPARATOR
Intervention: No growth hormone (NS) in A(0) and B(0) groups
Number of subjects: 210
Study 20021912 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 U/(kg.d) growth hormone in A(1) and B(1) groups
Number of subjects: 210
Study 16703541 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate 1% (Ophthalin)
Number of subjects: 110
Study 16703541 — intervention group
Group type: COMPARATOR
Intervention: 2% hydroxypropyl methylcellulose (HPMC-Ophtal)
Number of subjects: 110
Study 14628282 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Number of subjects: 134
Study 14628282 — intervention group
Group type: COMPARATOR
Intervention: Indinavir
Number of subjects: 134
Study 11127254 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC-medicated salt (0.33% w/w) for 10 days
Number of subjects: 40
Study 11127254 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC-medicated salt (0.33% w/w)
Number of subjects: 40
Study 11127254 — intervention group
Group type: COMPARATOR
Intervention: Normal cooking salt (control)
Number of subjects: 40
Study 9120921 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat injections
Number of subjects: 67
Study 9120921 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen injections
Number of subjects: 67
Study 8443252 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week educational and walking program
Number of subjects: 102
Study 8443252 — intervention group
Group type: COMPARATOR
Intervention: Weekly telephone survey
Number of subjects: 102
Study 3537462 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneovenous shunt (N = 10)
Number of subjects: 20
Study 3537462 — intervention group
Group type: COMPARATOR
Intervention: Medical Therapy (N = 10)
Number of subjects: 20
Study 31739753 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice condition (10 sessions of Stroop Test)
Number of subjects: 93
Study 31739753 — intervention group
Group type: COMPARATOR
Intervention: Control condition (pretest and posttest only)
Number of subjects: 93
Study 31739753 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice condition (older adults with higher educational level)
Number of subjects: 93
Study 31739753 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice condition (older adults)
Number of subjects: 93
Study 31419322 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPw (cellular Bordetella pertussis vaccine)
Number of subjects: 265
Study 31419322 — intervention group
Group type: COMPARATOR
Intervention: DTPa (acellular Bordetella pertussis vaccine)
Number of subjects: 265
Study 29016822 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion-Plus-Escitalopram
Number of subjects: 166
Study 29016822 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram-Plus-Placebo
Number of subjects: 166
Study 29016822 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine-Plus-Mirtazapine
Number of subjects: 166
Study 26409158 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance & Commitment Therapy (ACT)
Number of subjects: 238
Study 26409158 — intervention group
Group type: COMPARATOR
Intervention: Expressive Writing (Control)
Number of subjects: 238
Study 26409158 — intervention group
Group type: COMPARATOR
Intervention: Waiting list condition (Control)
Number of subjects: 238
Study 24019539 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX chemotherapy
Number of subjects: 2686
Study 24019539 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAF(V600E) mutations
Number of subjects: 2686
Study 24019539 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS mutations
Number of subjects: 2686
Study 21300246 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate pretreatment oral hygiene
Number of subjects: 230
Study 21300246 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys
Number of subjects: 230
Study 21300246 — intervention group
Group type: EXPERIMENTAL
Intervention: Diseased first molars
Number of subjects: 230
Study 21300246 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 230
Study 21300246 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of WSLs
Number of subjects: 230
Study 19741484 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (0-12 microg/ml) and Sevoflurane (0-3.5 vol.%)
Number of subjects: 60
Study 19741484 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (0-12 microg/ml)
Number of subjects: 60
Study 19741484 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (0-3.5 vol.%)
Number of subjects: 60
Study 17012720 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice
Number of subjects: 15
Study 17012720 — intervention group
Group type: COMPARATOR
Intervention: Fluoride dentifrice (control)
Number of subjects: 15
Study 15104193 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated pest management intervention (filling holes with copper mesh, vacuuming and cleaning, using low-toxicity pesticides and traps)
Number of subjects: 18
Study 15104193 — intervention group
Group type: COMPARATOR
Intervention: Control homes (no intervention)
Number of subjects: 18
Study 15104193 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated pest management intervention
Number of subjects: 18
Study 15104193 — intervention group
Group type: COMPARATOR
Intervention: Control homes
Number of subjects: 18
Study 11352440 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400mg administered orally after 250g of yoghurt
Number of subjects: 12
Study 11352440 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400mg administered orally under fasting conditions
Number of subjects: 12
Study 9499661 — intervention group
Group type: EXPERIMENTAL
Intervention: Motile neutrophils
Number of subjects: 0
Study 9499661 — intervention group
Group type: EXPERIMENTAL
Intervention: Motile monocytes
Number of subjects: 0
Study 9499661 — intervention group
Group type: COMPARATOR
Intervention: Resting neutrophils and monocytes
Number of subjects: 0
Study 8200006 — intervention group
Group type: EXPERIMENTAL
Intervention: Single high dose dactinomycin (60 mcg/kg x 1 day)
Number of subjects: 176
Study 8200006 — intervention group
Group type: COMPARATOR
Intervention: Standard fractionated dactinomycin (15 mcg/kg x 5 days)
Number of subjects: 176
Study 2965631 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion at 0.4 pmol min-1 kg-1
Number of subjects: 6
Study 2965631 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion at 2 pmol min-1 kg-1
Number of subjects: 6
Study 2965631 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion at 10 pmol min-1 kg-1
Number of subjects: 6
Study 2965631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2965631 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion
Number of subjects: 6
Study 29677572 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 173
Study 28860599 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk prediction model for ESRD
Number of subjects: 24104
Study 26138018 — intervention group
Group type: EXPERIMENTAL
Intervention: Duke Anticoagulation Satisfaction Scale (DASS)
Number of subjects: 326
Study 26138018 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Form Health Survey (SF-12)
Number of subjects: 326
Study 26138018 — intervention group
Group type: COMPARATOR
Intervention: INR control
Number of subjects: 326
Study 24640666 — intervention group
Group type: EXPERIMENTAL
Intervention: levofloxacin (Glevo) 500 mg/day
Number of subjects: 147
Study 24640666 — intervention group
Group type: COMPARATOR
Intervention: original levofloxacin 500 mg/day
Number of subjects: 147
Study 24640666 — intervention group
Group type: COMPARATOR
Intervention: standard therapy
Number of subjects: 147
Study 21671419 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral approach
Number of subjects: 701
Study 21671419 — intervention group
Group type: COMPARATOR
Intervention: Control group (active management advice)
Number of subjects: 701
Study 19178516 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide LAR 20 mg every 28 days
Number of subjects: 104
Study 19178516 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 104
Study 17162624 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg/d)
Number of subjects: 395
Study 17162624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study 15538079 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antioxidants (oxygenated carotenoid - lutein)
Number of subjects: 50
Study 11524488 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular cognitive impairment without dementia (CIND)
Number of subjects: 149
Study 11524488 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with vascular cognitive impairment without dementia (CIND)
Number of subjects: 149
Study 11524488 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants alive without dementia after 5 years
Number of subjects: 149
Study 11524488 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort of vascular CIND
Number of subjects: 149
Study 9642972 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (1.5 to 3 mg daily)
Number of subjects: 4
Study 9642972 — intervention group
Group type: COMPARATOR
Intervention: Control (non-akathitic schizophrenic patients)
Number of subjects: 4
Study 8495680 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine and 0.005% alfentanil (n = 31)
Number of subjects: 70
Study 8495680 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine (n = 29)
Number of subjects: 70
Study 2954800 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure porcine insulin
Number of subjects: 112
Study 2954800 — intervention group
Group type: COMPARATOR
Intervention: Partially purified bovine/porcine insulin
Number of subjects: 112
Study 2954800 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 112
Study 28870743 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based 2D-3D matched navigation group
Number of subjects: 80
Study 28870743 — intervention group
Group type: COMPARATOR
Intervention: Paired-point matched navigation group (PPM)
Number of subjects: 80
Study 26645257 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS) plus rehabilitation
Number of subjects: 21
Study 26645257 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation alone
Number of subjects: 21
Study 24157530 — intervention group
Group type: EXPERIMENTAL
Intervention: Living at 2,085 m
Number of subjects: 48
Study 24157530 — intervention group
Group type: EXPERIMENTAL
Intervention: Living at 2,454 m
Number of subjects: 48
Study 24157530 — intervention group
Group type: COMPARATOR
Intervention: Living at 1,780 m
Number of subjects: 48
Study 24157530 — intervention group
Group type: COMPARATOR
Intervention: Living at 2,800 m
Number of subjects: 48
Study 24157530 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 48
Study 23902631 — intervention group
Group type: EXPERIMENTAL
Intervention: Active deep brain stimulation to the ventral striatum/anterior limb of the internal capsule
Number of subjects: 10
Study 23902631 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 10
Study 23902631 — intervention group
Group type: EXPERIMENTAL
Intervention: Active deep brain stimulation
Number of subjects: 10
Study 20570290 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin continuous infusion (1 g every 6 hours for 18 hours after an initial 2 g dose)
Number of subjects: 20
Study 20570290 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin intermittent administration (1 g at 3, 9, and 15 hours after an initial 2 g dose)
Number of subjects: 20
Study 20570290 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin continuous infusion
Number of subjects: 20
Study 20570290 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin intermittent administration
Number of subjects: 20
Study 18990202 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxford Handicap Scale (OHS)
Number of subjects: 0
Study 18990202 — intervention group
Group type: EXPERIMENTAL
Intervention: OHS dichotomy separating patients with severe dependency or death
Number of subjects: 0
Study 18990202 — intervention group
Group type: EXPERIMENTAL
Intervention: OHS among survivors at hospital discharge
Number of subjects: 0
Study 21350689 — intervention group
Group type: EXPERIMENTAL
Intervention: OVD
Number of subjects: 62
Study 21350689 — intervention group
Group type: COMPARATOR
Intervention: BSS
Number of subjects: 62
Study 16135930 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 247
Study 16135930 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 247
Study 12124550 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 50 mg orally every 8 hours
Number of subjects: 41
Study 12124550 — intervention group
Group type: COMPARATOR
Intervention: Control group (no steroids or NSAIDs)
Number of subjects: 41
Study 12124550 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac-treated group
Number of subjects: 41
Study 12124550 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 9585797 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/day ipsapirone CR
Number of subjects: 18
Study 9585797 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day fluoxetine
Number of subjects: 18